Linc

Linc Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Linc (LINC.ST) as of Nov 20, 2026 is -1.06 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 2.28 % — a change of -146.69% (lower).

Cash Conversion

-1.06 %

YoY

-146.69%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Linc is 2025 -1.06 % . Cash Conversion Rate (OCF/Net Income) of Linc was 2024 2.28 % . It decreases by -146.69% lower compared to the previous year.

The Linc Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-6.22 SEK
Jan 1, 2019
0.20 SEK
Jan 1, 2020
-1.76 SEK
Jan 1, 2021
1,178.32 SEK
Jan 1, 2022
31.54 SEK
Jan 1, 2023
-13.01 SEK
Jan 1, 2024
2.28 SEK
Jan 1, 2025
-1.06 SEK
The Linc Cash Conversion history
YEARCash ConversionYoY
-1.06 %-146.69%
2.28 %-117.53%
-13.01 %-141.24%
31.54 %-97.32%
1,178.32 %-67,224.04%
-1.76 %-991.45%
0.20 %-103.17%
-6.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Cash Conversion Rate (OCF/Net Income) of Linc is -1.06 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Linc changed from 2.28 % to -1.06 %, representing a -146.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Linc since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Linc with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Linc

All Key Metrics — Linc